메뉴 건너뛰기




Volumn 57, Issue 6, 2013, Pages 2164-2170

Chronic hepatitis C virus (HCV) disease burden and cost in the United States

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FORECASTING; HEALTH CARE COST; HEPATITIS C; HUMAN; LIFE EXPECTANCY; PREVALENCE; PRIORITY JOURNAL; UNITED STATES;

EID: 84879113095     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26218     Document Type: Article
Times cited : (402)

References (47)
  • 2
    • 84857144025 scopus 로고    scopus 로고
    • The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007
    • Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278.
    • (2012) Ann Intern Med , vol.156 , pp. 271-278
    • Ly, K.N.1    Xing, J.2    Klevens, R.M.3    Jiles, R.B.4    Ward, J.W.5    Holmberg, S.D.6
  • 3
    • 33846403737 scopus 로고    scopus 로고
    • Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States
    • Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107-115.
    • (2007) J Viral Hepat , vol.14 , pp. 107-115
    • Deuffic-Burban, S.1    Poynard, T.2    Sulkowski, M.S.3    Wong, J.B.4
  • 4
    • 0033545541 scopus 로고    scopus 로고
    • Rising incidence of hepatocellular carcinoma in the United States
    • El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
    • (1999) N Engl J Med , vol.340 , pp. 745-750
    • El-Serag, H.B.1    Mason, A.C.2
  • 6
    • 84879098848 scopus 로고    scopus 로고
    • Waiting list candidates [Computer file]. Organ Procurement and Transplantation Network (OPTN). U.S. Dept. of Health and Human Services, Public Health Service, Bureau of Health Resources Development, Division of Organ Transplantation
    • Waiting list candidates [Computer file]. Organ Procurement and Transplantation Network (OPTN). U.S. Dept. of Health and Human Services, Public Health Service, Bureau of Health Resources Development, Division of Organ Transplantation; 2011.
    • (2011)
  • 7
    • 13644267743 scopus 로고    scopus 로고
    • Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security
    • Siebert U, Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005; 21: 55-65.
    • (2005) Int J Technol Assess Health Care , vol.21 , pp. 55-65
    • Siebert, U.1    Sroczynski, G.2
  • 8
    • 0030720484 scopus 로고    scopus 로고
    • Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C
    • Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-865.
    • (1997) Ann Intern Med , vol.127 , pp. 855-865
    • Bennett, W.G.1    Inoue, Y.2    Beck, J.R.3    Wong, J.B.4    Pauker, S.G.5    Davis, G.L.6
  • 9
    • 0034959828 scopus 로고    scopus 로고
    • Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden
    • Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36: 870-876.
    • (2001) Scand J Gastroenterol , vol.36 , pp. 870-876
    • Sennfalt, K.1    Reichard, O.2    Hultkrantz, R.3    Wong, J.B.4    Jonsson, D.5
  • 10
    • 33746595252 scopus 로고    scopus 로고
    • Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden
    • Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis 2006; 38: 497-505.
    • (2006) Scand J Infect Dis , vol.38 , pp. 497-505
    • Bernfort, L.1    Sennfalt, K.2    Reichard, O.3
  • 11
    • 0033799722 scopus 로고    scopus 로고
    • Estimating future hepatitis C morbidity, mortality, and costs in the United States
    • Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-1569.
    • (2000) Am J Public Health , vol.90 , pp. 1562-1569
    • Wong, J.B.1    McQuillan, G.M.2    McHutchison, J.G.3    Poynard, T.4
  • 12
    • 0038352047 scopus 로고    scopus 로고
    • Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population
    • Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-237.
    • (2003) JAMA , vol.290 , pp. 228-237
    • Salomon, J.A.1    Weinstein, M.C.2    Hammitt, J.K.3    Goldie, S.J.4
  • 14
    • 34447500595 scopus 로고    scopus 로고
    • A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels
    • Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg 2007; 70: 177-187.
    • (2007) Acta Gastroenterol Belg , vol.70 , pp. 177-187
    • Gerkens, S.1    Nechelput, M.2    Annemans, L.3    Peraux, B.4    Beguin, C.5    Horsmans, Y.6
  • 15
    • 75149163334 scopus 로고    scopus 로고
    • Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression
    • Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
    • (2010) Gastroenterology , vol.138 , pp. 513-521
    • Davis, G.L.1    Alter, M.J.2    El-Serag, H.3    Poynard, T.4    Jennings, L.W.5
  • 16
    • 79958733325 scopus 로고    scopus 로고
    • Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
    • Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int 2011; 31( Suppl 2): 4-17.
    • (2011) Liver Int , vol.31 , Issue.SUPPL. 2 , pp. 4-17
    • Kershenobich, D.1    Razavi, H.A.2    Cooper, C.L.3    Alberti, A.4    Dusheiko, G.M.5    Pol, S.6
  • 17
    • 84856239637 scopus 로고    scopus 로고
    • All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective
    • McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17: 531-546.
    • (2011) J Manag Care Pharm , vol.17 , pp. 531-546
    • McAdam-Marx, C.1    McGarry, L.J.2    Hane, C.A.3    Biskupiak, J.4    Deniz, B.5    Brixner, D.I.6
  • 18
    • 84857373298 scopus 로고    scopus 로고
    • Economic burden of hepatitis C-associated diseases in the United States
    • El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2012; 19: 153-160.
    • (2012) J Viral Hepat , vol.19 , pp. 153-160
    • El Khoury, A.C.1    Wallace, C.2    Klimack, W.K.3    Razavi, H.4
  • 19
    • 84868125609 scopus 로고    scopus 로고
    • University of California, Berkeley
    • Human mortality database, University of California, Berkeley; 2012.
    • (2012) Human mortality database
  • 20
    • 0032731788 scopus 로고    scopus 로고
    • Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C
    • Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. HEPATOLOGY 1999; 30: 1318-1324.
    • (1999) HEPATOLOGY , vol.30 , pp. 1318-1324
    • Younossi, Z.M.1    Singer, M.E.2    McHutchison, J.G.3    Shermock, K.M.4
  • 21
    • 73149113990 scopus 로고    scopus 로고
    • Public health impact of antiviral therapy for hepatitis C in the United States
    • Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. HEPATOLOGY 2009; 50: 1750-1755.
    • (2009) HEPATOLOGY , vol.50 , pp. 1750-1755
    • Volk, M.L.1    Tocco, R.2    Saini, S.3    Lok, A.S.4
  • 22
    • 84879123400 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention. Hepatitis surveillance. Hepatitis surveillance/Center for Disease Control Sept. 1 (Report 61).
    • Centers for Disease Control and Prevention. Hepatitis surveillance. Hepatitis surveillance/Center for Disease Control 2006 Sept. 1 (Report 61).
    • (2006)
  • 23
    • 33947519044 scopus 로고    scopus 로고
    • Surveillance for acute viral hepatitis-United States, 2005
    • Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveill Summ 2007; 56: 1-24.
    • (2007) MMWR Surveill Summ , vol.56 , pp. 1-24
    • Wasley, A.1    Miller, J.T.2    Finelli, L.3
  • 24
    • 40949100835 scopus 로고    scopus 로고
    • Surveillance for acute viral hepatitis-United States, 2006
    • Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008; 57: 1-24.
    • (2008) MMWR Surveill Summ , vol.57 , pp. 1-24
    • Wasley, A.1    Grytdal, S.2    Gallagher, K.3
  • 25
    • 67649297326 scopus 로고    scopus 로고
    • Surveillance for acute viral hepatitis-United States, 2007
    • Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 2009; 58: 1-27.
    • (2009) MMWR Surveill Summ , vol.58 , pp. 1-27
    • Daniels, D.1    Grytdal, S.2    Wasley, A.3
  • 28
    • 22044433989 scopus 로고    scopus 로고
    • Natural history of hepatitis C
    • Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-398.
    • (2005) Clin Liver Dis , vol.9 , pp. 383-398
    • Thomas, D.L.1    Seeff, L.B.2
  • 30
    • 84879116345 scopus 로고    scopus 로고
    • National Health and Nutrition Examination Survey Data, 2009-2010 Centers for Disease Control and Prevention. National Center for Health Statistics. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention
    • National Health and Nutrition Examination Survey Data, 2009-2010 Centers for Disease Control and Prevention. National Center for Health Statistics. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2012.
    • (2012)
  • 31
    • 0036690660 scopus 로고    scopus 로고
    • Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population
    • Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-979.
    • (2002) Transfusion , vol.42 , pp. 975-979
    • Dodd, R.Y.1    Notari, E.P.2    Stramer, S.L.3
  • 32
    • 77954324675 scopus 로고    scopus 로고
    • Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing
    • Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-1504.
    • (2010) Transfusion , vol.50 , pp. 1495-1504
    • Zou, S.1    Dorsey, K.A.2    Notari, E.P.3    Foster, G.A.4    Krysztof, D.E.5    Musavi, F.6
  • 33
    • 33846408285 scopus 로고    scopus 로고
    • Injection drug users in the United States, 1979-2002: an aging population
    • Armstrong GL. Injection drug users in the United States, 1979-2002: an aging population. Arch Intern Med 2007; 167: 166-173.
    • (2007) Arch Intern Med , vol.167 , pp. 166-173
    • Armstrong, G.L.1
  • 34
    • 34547428001 scopus 로고    scopus 로고
    • Predictors of response of US veterans to treatment for the hepatitis C virus
    • Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. HEPATOLOGY 2007; 46: 37-47.
    • (2007) HEPATOLOGY , vol.46 , pp. 37-47
    • Backus, L.I.1    Boothroyd, D.B.2    Phillips, B.R.3    Mole, L.A.4
  • 36
    • 0033022946 scopus 로고    scopus 로고
    • Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study
    • Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Mazzoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44: 874-880.
    • (1999) Gut , vol.44 , pp. 874-880
    • Bellentani, S.1    Pozzato, G.2    Saccoccio, G.3    Crovatto, M.4    Croce, L.S.5    Mazzoran, L.6
  • 37
    • 0030933395 scopus 로고    scopus 로고
    • Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
    • Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.
    • (1997) Lancet , vol.349 , pp. 825-832
    • Poynard, T.1    Bedossa, P.2    Opolon, P.3
  • 38
    • 0036829652 scopus 로고    scopus 로고
    • Fibrosis and disease progression in hepatitis C
    • Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. HEPATOLOGY 2002; 36( 5 Suppl 1): S47-S56.
    • (2002) HEPATOLOGY , vol.36 , Issue.5 SUPPL. 1
    • Marcellin, P.1    Asselah, T.2    Boyer, N.3
  • 40
    • 78650823246 scopus 로고    scopus 로고
    • Impact of a sustained virological response on the long-term outcome of hepatitis C
    • Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int 2011; 31( Suppl 1): 18-22.
    • (2011) Liver Int , vol.31 , Issue.SUPPL. 1 , pp. 18-22
    • Alberti, A.1
  • 41
    • 79961199944 scopus 로고    scopus 로고
    • Hepatitis C virus infection in the United States: an estimate of true prevalence
    • Chak E, Talal A, Sherman KE, Schiff E, Saab S. Hepatitis C virus infection in the United States: an estimate of true prevalence. Liver Int 2011; 31: 1090-1101.
    • (2011) Liver Int , vol.31 , pp. 1090-1101
    • Chak, E.1    Talal, A.2    Sherman, K.E.3    Schiff, E.4    Saab, S.5
  • 42
    • 84867288022 scopus 로고    scopus 로고
    • Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
    • Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.
    • (2012) MMWR Recomm Rep , vol.61 , pp. 1-32
  • 44
    • 0027068086 scopus 로고
    • The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team
    • Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905.
    • (1992) N Engl J Med , vol.327 , pp. 1899-1905
    • Alter, M.J.1    Margolis, H.S.2    Krawczynski, K.3    Judson, F.N.4    Mares, A.5    Alexander, W.J.6
  • 45
    • 0033023854 scopus 로고    scopus 로고
    • Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
    • Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. HEPATOLOGY 1999; 29: 908-914.
    • (1999) HEPATOLOGY , vol.29 , pp. 908-914
    • Villano, S.A.1    Vlahov, D.2    Nelson, K.E.3    Cohn, S.4    Thomas, D.L.5
  • 46
    • 49649118223 scopus 로고    scopus 로고
    • Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression
    • Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. HEPATOLOGY 2008; 48: 418-431.
    • (2008) HEPATOLOGY , vol.48 , pp. 418-431
    • Thein, H.H.1    Yi, Q.2    Dore, G.J.3    Krahn, M.D.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.